Download Unicorn Signals App

Powered By EquityPandit

EquityPandit

EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Sun Pharma has received USFDA approval for eye inflammation drug

Sun Pharmaceutical Industries Ltd. signage is displayed outside the company's corporate office in the Andheri suburb of Mumbai, India, on Monday, April 7, 2014. Sun Pharmaceutical, India's largest drugmaker by market value, agreed to buy Ranbaxy Laboratories Ltd. for $3.2 billion in stock, the biggest purchase by an Indian company in two years. Photographer: Amit Madheshiya/Bloomberg via Getty Images

Sun Pharmaceutical Industries has got the US health regulator’s approval for its non-steroid drug BromSite which is used in treating inflammation and to prevent pain in patients undergoing cataract surgery.

Sun Pharmaceutical Industries has said in a BSE filing that One of the company’s wholly-owned subsidiaries “has received approval from USFDA for its New Drug Application (NDA) related to BromSite (bromfenac ophthalmic solution) 0.075 percent for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.”

It further added that the drug has been developed by InSite Vision that the company had acquired in November 2015.

Read EquityPandit’s Nifty Pharma Outlook for this week 

Get Daily Prediction & Stocks Tips On Your Mobile


@2024 - www.equitypandit.com. All Right Reserved. Designed and Developed by PenciDesign